On Thursday, Oppenheimer reiterated its Outperform rating on shares of Neurocrine (NASDAQ:NBIX) Biosciences (NASDAQ:NBIX), currently trading at $141.24, with a steady price target of $192.00. The firm ...

There are also the unicorns: crewneck sweatshirts that are both luxuriously oversize and effortlessly chic. (Think Princess Diana out on the town.) To find an array of options that span the Venn ...

On Thursday, Oppenheimer reiterated its Outperform rating on shares of Neurocrine (NASDAQ:NBIX) Biosciences (NASDAQ:NBIX), currently trading at $141.24, with a steady price target of $192.00.

Neurocrine Bioscience Inc. said in a federal lawsuit that Spruce Biosciences Inc. is threatening patent litigation over its new rare disease drug Crenessity due to a “desperate need for cash”.

BMO Capital analyst Evan Seigerman maintained a Hold rating on Neurocrine (NBIX – Research Report) yesterday and set a price target of $121.00. Discover outperforming stocks and invest smarter ...

An End of Phase 2 meeting for NBI-1117568 (NBI-’568, an oral, muscarinic M4 selective agonist) has been completed with the US Food & Drug Administration and Neurocrine reiterated its intentions ...

Tokyo, Japan and Cambridge, UK, 14 January 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) is pleased to report on progress being made by Neurocrine Biosciences ...

Tokyo, Japan and Cambridge, UK, 14 January 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) is pleased to report on progress being made by Neurocrine Biosciences, Inc. (“Neurocrine”) ...

Ashley Allan is making history in her role as executive director for CAH brand marketing at Neurocrine Biosciences, overseeing a cross-functional team that launched the first treatment for CAH (a ...